Instrument Developed to Assess Quality of Life in Meniere Disease
By Elana Gotkine HealthDay Reporter
FRIDAY, May 3, 2024 -- A brief, valid instrument has been developed for assessing quality of life in Meniere disease, according to a study published online April 30 in The Laryngoscope.
Alexandra E. Quimby, M.D., M.P.H., from the Hospital of the University of Pennsylvania in Philadelphia, and colleagues created a 24-item Meniere disease quality of life (MenQOL) instrument using a sequential process of expert input, patient focus groups, and analyses of responses to draft questionnaires. The MenQOL and Short-Form-36 version 2 (SF-36v2) were administered to 50 patients with Meniere disease and 60 patients with tinnitus, vertigo, or hearing loss from other causes.
The researchers found that the MenQOL has a single domain based on exploratory factor analysis. For the instrument as a whole, a Cronbach's α score of 0.914 indicated high internal consistency. Relative to comparison patients, patients with Meniere disease had significantly worse quality of life based on mean MenQOL scores (52.5 ± 15.8 versus 43.2 ± 12.6), indicating good construct validity. In bivariate linear regressions, significant inverse relationships were seen between total MenQOL scores and SF-36v2 physical and mental composite scores, indicating acceptable concurrent validity (slopes, −0.94 and −1.16, respectively).
"Subsequent to further study confirming validity and examining changes over time and in response to treatment, we hope that the instrument may become a widely adopted disease-specific QOL scale for use in Meniere disease," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted May 2024
Read this next
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
Self-Administered Gerocognitive Exam Improves Detection of Cognitive Issues in Primary Care
TUESDAY, July 2, 2024 -- A self-administered gerocognitive examination (SAGE) is easily incorporated into primary care provider (PCP) visits, and its use significantly increases...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.